Company announcement – No. 49 / 2020
Original post:
Zealand Pharma grants warrants and restricted share units under the employee warrant program and management long-term incentive program
LYON, France, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Article 223-16 of general regulation of French Autorité des Marchés Financiers Lyon – France
The rest is here:
Monthly information related to total number of voting rights and shares composing the share capital – August 31, 2020
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
Read more:
Dr. Jean-Christophe Rufin appointed President of the Sanofi Espoir Corporate Foundation
NEW YORK, Sept. 17, 2020 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 7,142,857 shares of common stock of the Company, at a price to the public of $2.80 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about September 22, 2020, subject to satisfaction of customary closing conditions.
Originally posted here:
Checkpoint Therapeutics Announces $20.0 Million Bought Deal Offering
CANTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that the date and time of its presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit has been updated.
Continue reading here:
Organogenesis Holdings Inc. Updates Date and Time of Presentation at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
- AUTO3 shows promise of a highly differentiated product profile
Read the original here:
Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ESMO Virtual Congress 2020
SYDNEY, Australia, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) is pleased to report further interim data from its ongoing INSIGHT-004 Phase I clinical trial. The data were presented at the ESMO Virtual Congress 2020 on 17 September 2020, CEST (poster ID number 1032P) by trial investigator at Institute of Clinical Cancer Research, Krankenhaus Nordwest (IKF), PD Dr. Thorsten Götze.
Follow this link:
Immutep Reports Improving Results from INSIGHT-004 Trial
Dr. James Woody’s leadership qualities and experience leading innovative pharmaceutical ventures and raising funds will power Enosi’s development of second-generation anti-TNF therapeutics for inflammatory autoimmune diseases and cancer.
